TriangleNCT02875561 · REGISTRY CONDITION SEARCH
Ultrasonic Aspiration Versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- NA
- Status at capture
- COMPLETED
- Registry last update
- 2023-11-18
The primary objective of this study is to evaluate the incidence of vulva dysplasia recurrence within 12 months of treatment with Carbon Dioxide (CO2) laser ablation or ultrasonic aspiration.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Women 18-89 years old * Women diagnosed with high-grade VIN (diagnosed by pathology) * Women referred for vulva sparing treatment for dysplasia * Women available for follow-up of treatment for 12 months Exclusion Criteria: * Women who are pregnant * Women with low-grade VIN dysplasia (diagnosed by pathology) * Women with vaginal intraepithelial neoplasia(VAIN) * Women requiring vulvectomy for treatment * Women unable to provide informed consent
- healthy Volunteers
- false
- maximum Age
- 89 Years
- minimum Age
- 18 Years
- sex
- FEMALE
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Treatment of VIN dysplasia with sonopet ultrasonic aspirator: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
- intervention Names
- Device: Sonopet Ultrasonic Aspirator
- label
- Sonopet Ultrasonic Aspirator
- type
- ACTIVE_COMPARATOR
- description
- Treatment of VIN dysplasia with CO2 Laser Ablation: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
- intervention Names
- Device: CO2 Laser Ablation
- label
- CO2 Laser Ablation
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Sonopet Ultrasonic Aspirator
- description
- To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
- name
- Sonopet Ultrasonic Aspirator
- type
- DEVICE
- arm Group Labels
- CO2 Laser Ablation
- description
- To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
- name
- CO2 Laser Ablation
- type
- DEVICE
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- SINGLE
- who Masked
- OUTCOMES_ASSESSOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 47
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Number of participants with recurrence of dysplasia time point 12 months
- measure
- Number of Participants With Recurrence of Dysplasia
- time Frame
- 12 months
- secondary Outcomes
- description
- Physical evaluation for scarring
- measure
- Number of Participants With Scarring
- time Frame
- 6 weeks
- description
- Evaluated by Female Sexual Function Index Scale Title: Female Sexual Function Index (FSFI) Minimum value: 2.0 Maximum value: 36.0 a score of 0 in any domain correlates to no sexual activity. a score of 0 in any domain correlates to no sexual activity in that domain alone, and is not indicative of the total score. Lower scores indicate worse sexual function.
- measure
- Changes in Sexual Function
- time Frame
- Baseline (enrollment), 12 months
- description
- Evaluated by Functional Assessment of Cancer Therapy - Vulva (FACT-V) health survey for vulva disease Scale Title: Functional Assessment of Cancer Therapy - Vulva (FACT-V) High score correlates to better quality of life. This survey uses a 5-point Likert type scale. Minimum score: 0 Maximum score: 184
- measure
- Changes in Mental and Physical Wellness
- time Frame
- Baseline (enrollment), End of Study (12 months)
Full study description
- brief Summary
- The primary objective of this study is to evaluate the incidence of vulva dysplasia recurrence within 12 months of treatment with Carbon Dioxide (CO2) laser ablation or ultrasonic aspiration.
- detailed Description
- Incidence of Vulvar Intraepithelial Neoplasia (VIN) is increasing among women and there still lacks a standard of care for optimal treatment. Current treatment options aim to treat the symptoms associated with VIN and result in a high recurrence rate. Due to the high reoccurrence rate and the nature of the current treatments, a more effective treatment option is warranted. An effective treatment that targets only the diseased areas could potentially decrease recurrence rates. Additionally, a more conservative treatment modality could contribute to reduced risks of scarring, discomfort, and psychosocial and sexual distraught. The researchers hypothesize that treatment for VIN with ultrasonic aspiration will have a 60% reduction in recurrence rates over 12 months as compared to CO2 laser aspiration. This study will employ a randomized controlled trial (RCT) design. This is a phase III study to determine the effectiveness of a more targeted treatment therapy for VIN (comparing ultrasonic aspiration versus CO2 laser ablation). Potential participants will be identified through the gynecological clinical practices following diagnosis of high grade VIN and will be randomized (1:1) to one of the treatment therapies. Randomization will be stratified for multi-focal disease and Human Papillomavirus (HPV) status. Both the Sonopet Ultrasonic Aspirator and the CO2 laser ablation devices are FDA approved devices for the treatment of vulvar dysplasia.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-6c03884be0cc27d1d9eb
- requested nct id
- NCT02875561
- primary nct id
- NCT02875561
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 9c84fe83f9fcdb12f3a6bb624863442db2afcee53df61c38a03e4f013f7f76a1
- payload sha256
- dd678610089b5cfb9642d160f3d824faac60581b8f95dc46bbff0c4f302da8a9
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-6c03884be0cc27d1d9eb
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT02875561
- occurrences
- context exact
- NCT02875561
- end
- 11
- exact text
- NCT02875561
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Vulvar Cancer
- query disease state id
- ds-vulvar-cancer
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-vulvar-cancer-000.json
- source file sha256
- 9c84fe83f9fcdb12f3a6bb624863442db2afcee53df61c38a03e4f013f7f76a1
- source json pointer
- /studies/23/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 033708c819ac7318437186ecfb363603e2c97de6e301365e5d85072d52f8e57e
Preserved source evidence · Not medical advice